On August 26, 2026, a trial update was recorded for NCT07576036, a study relevant to desmopressin use in hyponatremia management. The trial is titled "International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia." Its current status is listed as enrolling by invitation. No phase designation was provided for this study in the available record.
The study is retrospective in design and international in scope, involving multiple centers. It focuses on patients with serum sodium levels at or below 110 mmol/L, examining the relationship between rapid correction of hyponatremia and the occurrence of osmotic demyelination syndrome. Desmopressin is an approved compound sometimes used in the clinical management of sodium correction, which is the context for its inclusion in this trial record.
No outcome data, results, or conclusions have been reported as part of this update. The listing reflects only the enrollment status and study design details as registered. Readers can consult the compound overview for further background on desmopressin and its approved uses.